Pfizer
PURPOSE BLUEPRINT 2.0 & STRATEGIC EXECUTION
PURPOSE BLUEPRINT 2.0
Change 1 Billion Lives a Year by
2027
Current Strategic Therapeutic Focus Areas
ONCOLOGY
Advancing innovative approaches across
major cancer challenges and strengthening
pipeline capabilities.
INTERNAL MEDICINE
Addressing cardiovascular and metabolic
needs, including focus on obesity and
cardiometabolic disease.
VACCINES
Developing and advancing vaccines designed
to prevent infectious disease and protect
public health.
INFLAMMATION & IMMUNOLOGY
Seeking therapies that transform the
management of inflammatory and immune-
mediated diseases.
AN ACCORD FOR A HEALTHIER WORLD
Established to expand access to Pfizer's patented, high-quality medicines and vaccines on a not-for-
profit basis in 45 lower-income countries. This includes our full portfolio for which we hold global
rights.
INNOVATION → ACCESS → HEALTH EQUITY
STRATEGY FRAMEWORK
This ambition marks a shift from counting breakthroughs to measuring the depth of our
impact. Our methodology for estimating lives impacted uses company and third-party
datasets and includes estimates and methodological limitations.